Serum biomarkers in severe refractory cardiogenic shock

JACC: Heart Failure

Volumn 1, Issue 3, 2013, Pages 200-206

  Shah, Nishant R ^a   Bieniarz, Mark C ^b   Basra, Sukhdeep S ^a   Paisley, Robert D ^c   Loyalka, Pranav ^d   Gregoric, Igor D ^d   Mann, Douglas L ^e   Kar, Biswajit ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b New Mexico Heart Institute   (United States)

^c Joint Base Elmendorf Richardson   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Biomarkers; Cardiogenic shock; Heart failure; Percutaneous left ventricular assist device

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; COLLAGEN TYPE 3; ENDOTHELIN 1; FAS ANTIGEN; FAS LIGAND; TUMOR NECROSIS FACTOR RECEPTOR 1;

ADULT; ARTICLE; BLOOD SAMPLING; CARDIOGENIC SHOCK; CLINICAL ARTICLE; DISEASE SEVERITY; ENZYME ACTIVITY; FEMALE; HEART HEMODYNAMICS; HUMAN; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; QUALITATIVE ANALYSIS; SEVERE REFRACTORY CARDIOGENIC SHOCK; VENTRICULAR ASSIST DEVICE; WILCOXON SIGNED RANKS TEST;

BIOMARKERS; CARDIOGENIC SHOCK; HEART FAILURE; PERCUTANEOUS LEFT VENTRICULAR ASSIST DEVICE;

BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SHOCK, CARDIOGENIC;

EID: 84878640745     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2013.03.002     Document Type: Article

References (22)

1. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. N Engl J Med 1999, 341:625-634. SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) Investigators.
2. Holmes D.R., Bates E.R., Kleiman N.S., et al. Contemporary reperfusion therapy for cardiogenic shock: the GUSTO-I trial experience. J Am Coll Cardiol 1995, 26:668-674. GUSTO-I (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) Investigators.
3. Babaev A., Frederick P.D., Pasta D.J., Every N., Sichrovsky T., Hochman J.S. Trends in management and outcomes of patients with acute myocardial infarction complicated by cardiogenic shock. JAMA 2005, 294:448-454.
4. Scheidt S., Wilner G., Mueller H., et al. Intra-aortic balloon counterpulsation in cardiogenic shock. Report of a co-operative clinical trial. N Engl J Med 1973, 288:979-984.
5. Anderson R.D., Ohman E.M., Holmes D.R., et al. Use of intraaortic balloon counterpulsation in patients presenting with cardiogenic shock: observations from the GUSTO-I (Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries) study. J Am Coll Cardiol 1997, 30:708-715.
6. Sanborn T.A., Sleeper L.A., Bates E.R., et al. Impact of thrombolysis, intra-aortic balloon pump counterpulsation, and their combination in cardiogenic shock complicating acute myocardial infarction: a report from the SHOCK (Should We Emergently Revascularize Occluded Coronaries for Cardiogenic Shock) trial registry. J Am Coll Cardiol 2000, 36:1123-1129.
7. Barron H.V., Every N.R., Parsons L.S., et al. The use of intra-aortic balloon counterpulsation in patients with cardiogenic shock complicating acute myocardial infarction: data from the National Registry of Myocardial Infarction 2. Am Heart J 2001, 141:933-939.
8. Thiele H., Lauer B., Hambrecht R., Boudriot E., Cohen H.A., Schuler G. Reversal of cardiogenic shock by percutaneous left atrial-to-femoral arterial bypass assistance. Circulation 2001, 104:2917-2922.
9. Idelchik G.M., Simpson L., Civitello A.B., et al. Use of the percutaneous left ventricular assist device in patients with severe refractory cardiogenic shock as a bridge to long-term left ventricular assist device implantation. J Heart Lung Transplant 2008, 27:106-111.
10. Kar B., Gregoric I.D., Basra S.S., Idelchik G.M., Loyalka P. The percutaneous ventricular assist device in severe refractory cardiogenic shock. J Am Coll Cardiol 2011, 57:688-696.
11. Reynolds H.R., Hochman J.S. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008, 117:686-697.
12. Nakatani S., McCarthy P.M., Kottke-Marchant K., et al. Left ventricular echocardiographic and histologic changes: impact of chronic unloading by an implantable ventricular assist device. J Am Coll Cardiol 1996, 27:894-901.
13. Maybaum S., Mancini D., Xydas S., et al. Cardiac improvement during mechanical circulatory support: a prospective multicenter study of the IVAD working group. Circulation 2007, 115:2497-2505.
14. Bruggink A.H., de Jonge N., van Oosterhout M.F., et al. Brain natriuretic peptide is produced both by cardiomyocytes and cells infiltrating the heart in patients with severe heart failure supported by a left ventricular assist device. J Heart Lung Transplant 2006, 25:174-180.
15. Cheng J., Zhou T., Liu C., et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994, 263:1759-1762.
16. Bartling B., Milting H., Schumann H., et al. Myocardial gene expression of regulators of myocyte apoptosis and myocyte calcium homeostasis during hemodynamic unloading by ventricular assist devices in patients with end-stage heart failure. Circulation 1999, 100:II216-II223.
17. James K.B., McCarthy P.M., Thomas J.D., et al. Effect of the implantable left ventricular assist device on neuroendocrine activation in heart failure. Circulation 1995, 92:II191-II195.
18. Delgado R., Radovancevic B., Massin E.K., Frazier O.H., Benedict C. Neurohormonal changes after implantation of a left ventricular assist system. ASAIO J 1998, 44:299-302.
19. Li Y.Y., Feng Y., McTiernan C.F., et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001, 104:1147-1152.
20. Bruckner B.A., Stetson S.J., Perez-Verdia A., et al. Regression of fibrosis and hypertrophy in failing myocardium following mechanical circulatory support. J Heart Lung Transplant 2001, 20:457-464.
21. Bruggink A.H., van Oosterhout M.F., de Jonge N., et al. Reverse remodeling of the myocardial extracellular matrix after prolonged left ventricular assist device support follows a biphasic pattern. J Heart Lung Transplant 2006, 25:1091-1098.
22. Thiele H., Sick P., Boudriot E., et al. Randomized comparison of intra-aortic balloon support with a percutaneous left ventricular assist device in patients with revascularized acute myocardial infarction complicated by cardiogenic shock. Eur Heart J 2005, 26:1276-1283.